Daily chocolate consumption is inversely associated with insulin resistance and liver enzymes in the Observation of Cardiovascular Risk Factors in Luxembourg study

Ala’a Alkerwi1*, Nicolas Sauvageot1, Georgina E. Crichton1,2, Merrill F. Elias3,4 and Saverio Stranges1,5
1Luxembourg Institute of Health (LIH) (formerly CRP-Santé), Epidemiology and Public Health Research Unit, Strassen, L-1445, Grand-Duchy of Luxembourg
2Nutritional Physiology Research Centre, University of South Australia, Adelaide 5001, Australia
3Department of Psychology, University of Maine, Orono, ME 04469, USA
4Graduate School of Biomedical Science and Engineering, University of Maine, Orono, ME 04469, USA
5Division of Health Sciences, University of Warwick Medical School, Coventry CV4 7AL, UK

(Submitted 16 November 2015 – Final revision received 13 January 2016 – Accepted 1 February 2016 – First published online 17 March 2016)

Abstract
This study examined the association of chocolate consumption with insulin resistance and serum liver enzymes in a national sample of adults in Luxembourg. A random sample of 1153 individuals, aged 18–69 years, was recruited to participate in the cross-sectional Observation of Cardiovascular Risk Factors in Luxembourg study. Chocolate consumption (g/d) was obtained from a semi-quantitative FFQ. Blood glucose and insulin levels were used for the homoeostasis model assessment of insulin resistance (HOMA-IR). Hepatic biomarkers such as serum γ-glutamyl-transpeptidase (γ-GT), serum aspartate transaminase and serum alanine transaminase (ALT) (mg/l) were assessed using standard laboratory assays. Chocolate consumers (81·8%) were more likely to be younger, physically active, affluent people with higher education levels and fewer chronic co-morbidities. After excluding subjects taking antidiabetic medications, higher chocolate consumption was associated with lower HOMA-IR (β = −0·16, P = 0·004), serum insulin levels (β = −0·16, P = 0·003) and γ-GT (β = −0·12, P = 0·009) and ALT (β = −0·09, P = 0·004), after adjustment for age, sex, education, lifestyle and dietary confounding factors, including intakes of fruits and vegetables, alcohol, polyphenol-rich coffee and tea. This study reports an independent inverse relationship between daily chocolate consumption and levels of insulin, HOMA-IR and liver enzymes in adults, suggesting that chocolate consumption may improve liver enzymes and protect against insulin resistance, a well-established risk factor for cardiometabolic disorders. Further observational prospective research and well-designed randomised-controlled studies are needed to confirm this cross-sectional relationship and to comprehend the role and mechanisms that different types of chocolate may play in insulin resistance and cardiometabolic disorders.

Key words: Insulin resistance: Liver enzymes: Chocolate consumption

Atherosclerotic CVD is the leading killer in the adult population of Western societies(1). Obesity, diabetes and insulin resistance are metabolic disorders and well-known risk factors for CVD(2–4). Hyperinsulinaemia has been associated with an increased cardiovascular risk in non-diabetic subjects, and has been related to a number of other conditions such as hypertension, dyslipidaemia and central body fat distribution(5). These pathologies are escalating worldwide and constitute an important concern to public health authorities.

Cocoa research has received much attention over recent years. Chocolate may have beneficial cardiometabolic effects, possibly due to cocoa polyphenols. Cocoa beans and its derivatives contain different types of physiologically active compounds including, among others, polyphenols and their flavonoids subclasses(6,7). Cocoa, especially dark chocolate, represents a noteworthy source of flavonoids as it contains considerably higher concentrations of flavonoids per serving than tea, apple and red wine(8,9), contributing to its higher antioxidant capacity and, presumably, to its beneficial health effects(10). Epidemiological data suggest that flavonoid intake from different sources may reduce the risk of CHD(11–13) and stroke(14) and is inversely associated with coronary mortality(15). A recent experimental study on obese mice reported that cocoa supplementation attenuated insulin resistance, as indicated by improved homoeostasis model assessment of insulin resistance (HOMA-IR), and reduced the severity of
obesity-related fatty liver disease, a condition implicated in diabetes risk. In line with these findings, a small, short-term, cross-over study has reported that cocoa ingestion improved insulin sensitivity in healthy subjects. Another small randomised trial showed increased insulin sensitivity in glucose-intolerant, hypertensive subjects after 15 d of consuming high-polyphenol dark chocolate. Thus far, evidence regarding a potential role of chocolate intake in insulin resistance and liver function from human epidemiological studies is lacking.

In the present study, we hypothesised that chocolate consumption may have a beneficial effect on insulin sensitivity and liver enzymes. Therefore, we examined whether daily chocolate consumption may be associated with insulin resistance and serum insulin and liver enzyme levels in a national sample of adults in Luxembourg, taking into account potential confounding lifestyle and dietary factors, including the simultaneous consumption of polyphenol-rich tea and coffee beverages.

Methods
Study design and participants
Analyses were based on data from the Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) survey, a nationwide population-based, cross-sectional study of the adult population in Luxembourg. More details of the study design, sample selection and data collection have been previously reported. In brief, a stratified random sample of 1432 participants, aged 18–69 years, was recruited between November 2007 and January 2009. Trained research staff provided the participants with detailed instructions on how to complete the self-administered FFQ, assisted them in completing questions on dietary information and then checked the completeness and accuracy of responses. After data cleaning, particularly for poorly completed dietary data, 1352 participants were available for the present study. Analyses were carried out with a set of 1153 subjects after eliminating those who reported eating during the survey period (n = 199).

The ORISCAV-LUX study was conducted according to the guidelines laid down in the Declaration of Helsinki. All procedures involving human subjects were approved by the National Research Ethics Committee (N 200609/03) and the National Commission for Private Data Protection. Written informed consent was obtained from all subjects.

Insulin resistance and liver biomarkers (dependent variables)
Standard laboratory assays were used to assess several biomarkers including fasting plasma glucose (FPG, mg/dl), serum insulin (µg/l), glycated Hb (HbA1c) in percentage values and hepatic biomarkers (serum γ-glutamyl-transpeptidase (γ-GT), serum aspartate transaminase and serum alanine transaminase (ALT) (mg/l)). Similar to most epidemiological studies, the HOMA-IR was used as a feasible surrogate approach to assess insulin sensitivity, and was calculated as follows: HOMA-IR = (fasting glucose × fasting insulin)/22.5. Lower scores indicate higher insulin sensitivity.

Chocolate consumption (exposure-independent variables)
A semi-quantitative, 134-item FFQ was completed by the participants, including questions on habitual daily consumption of chocolate during the previous 3 months. The participants reported their frequency of consumption from six response options, ranging from ‘rarely or never’ (i.e. less than once per month) to ‘two or more times per d’. They also selected the serving size of chocolate based on a photographic manual provided as a reference (e.g. one portion is equal to one pre-packaged bar of chocolate). Frequency of consumption (times per d) × amount of chocolate consumed (g) represented daily chocolate consumption (g/d). To facilitate data interpretation, daily chocolate consumption was then multiplied by 100 to convert it to 100 g/d.

Covariates
Demographic and socio-economic data were obtained from a self-administered questionnaire (age, sex, education). Education was grouped into primary, secondary or tertiary levels. Detailed data regarding cigarette smoking were obtained from the health questionnaire, and each participant was classified as current smoker or non-smoker. Self-reported time per week spent engaging in physical activity was assessed using the International Physical Activity Questionnaire (IPAQ), and was used to classify the participants into ‘inactive’, ‘moderately active’ or ‘active’, based on scoring criteria of the IPAQ’s Research Committee.

BMI was calculated as weight (kg) divided by the square of height (m²), measured according to standard operating procedures using a digital column scale (Seca 701; Seca). Waist circumference (WC, cm) was measured at the level midway between the twelfth rib and the uppermost lateral border of the iliac crest during normal expiration. Standard laboratory assays were used to assess lipid biomarkers: TAG (mg/dl), HDL-cholesterol (mg/dl), LDL-cholesterol (mg/dl) and total cholesterol (mg/dl). Blood pressure (BP) was measured using an Omron M3 Plus automated oscillometric blood pressure monitor (O-HEM-742-E). Measurements were taken at least three times with the participants in a seated position and with a minimum interval of 5 min between each measurement. The average of the last two readings was used in the analysis. All these variables were measured according to ORISCAV-LUX standardised protocols and have been described in detail in previous publications.

Total daily energy intakes (kJ/d (kcal/d)), energy from total carbohydrates, sugars and added sugar, from total fat and SFA (all as %E) as well as from alcohol (ml/d), fruit and vegetable consumptions (g/d) were obtained from the FFQ. These variables have been described in detail elsewhere.

Statistical analysis
To describe chocolate consumption among the studied population, participants were classified into two groups: non-consumers and consumers. According to the type of variable (continuous or categorical), the Wilcoxon’s and χ² tests
were used to compare demographic, lifestyle and cardiometabolic characteristics across the groups according to daily chocolate consumption. For categorical variables, values were expressed as numbers and percentages, and for continuous variables values were expressed as mean values and standard deviations.

After exclusion of subjects taking hypoglycaemic medication (twenty-five subjects; 2.17%), linear regression analyses were performed to assess the association between chocolate consumption and FPG, HbA1c, HOMA-IR, insulin and liver enzymes. The coefficient of regression \(b\) was computed to predict how much a 100 g increase in chocolate consumption may increase or decrease each outcome variable. Three models with progressive adjustment were used:

1. Basic covariate set (model I): adjusted for age, sex, and education level (primary, secondary or tertiary).
2. Full covariate set (model II): basic + further adjustment for smoking status (smoker or non-smoker), physical activity (metabolic equivalent-min/week), fruit and vegetable intake (g/d), total daily energy intake (kJ/d (kcal/d)) and alcohol consumption (ml/d).
3. Extended covariate set (model III): full covariate set + further adjustment for coffee and tea consumption.

Potential confounding factors were identified and included in the models on the basis of two criteria: (1) had to show a statistically significant association \((P<0.05)\) with both chocolate consumption and any hepatic biomarker and (2) had to be theoretically or clinically relevant. Although BMI met the first criterion to be considered as a confounding variable, we decided not to include it in the multivariable models to avoid over-adjustment bias, defined as control for an intermediate variable (or a proxy for an intermediate variable) on a causal path from exposure to outcome\(^{(26)}\). BMI is likely to act as a mediator (or a proxy for another unmeasured intermediate variable), and thus intervene in the causal pathway of the chocolate–biomarkers relationships.

Plausible interactions between chocolate consumption and BMI were tested and found to be not significant. Several sensitivity analyses were performed to confirm the robustness of the presented findings. Results were considered significant at the 5% critical level \((P<0.05)\), two-sided. All statistical analyses were performed using SAS version 9.4.

Results

Chocolate consumption

More than 80% of the participants reported chocolate consumption, with an average daily consumption of 24.8 g/d (minimum 0.66; maximum 500.7) and median intake of 10.7 g/d (lower quintile = 5.4; upper quintile = 28.6).

Participant characteristics according to daily chocolate consumption

Globally, daily chocolate consumption varied significantly according to demographic, lifestyle and health factors of the ORISCAV-LUX participants (all \(P<0.05\)), except for sex \((P=0.7)\) and tobacco consumption \((P=0.11)\). Non-consumers were considerably more likely to have a lower education level, to be living below the poverty threshold and be physically inactive compared with chocolate consumers. Those who consumed chocolate were significantly younger \((43.1 v. 48.3\) years; \(P<0.0001)\). Cardiometabolic co-morbidities (obesity, diabetes and hypertension) were less frequent among chocolate consumers than non-consumers (Table 1). Table 2 describes dietary and cardiometabolic variables according to daily chocolate consumption. Chocolate consumers had significantly higher intakes of total energy \((P<0.0001)\) and total fats including SFA \((P<0.0001)\), but lower intakes of alcohol \((P=0.032)\), compared with their counterparts. Glycaemic parameters including FPG, HbA1c and HOMA-IR as well as BMI, WC and total cholesterol levels were significantly higher among non-consumers.

Association of chocolate consumptions with insulin resistance and liver biomarkers

Table 3 shows the multivariable regression analysis, relating chocolate consumption \((100\text{ g/d})\) to insulin resistance and hepatic markers. A tendency for an inverse relationship between all liver biomarkers and chocolate consumption was observed, indicated by negative regression coefficients \((b)\) for all the models.

Daily chocolate consumption was significantly associated with lower HOMA-IR \((P=0.004)\), serum insulin levels \((P=0.003)\) and liver enzymes including \(\gamma\)-GT \((P=0.009)\) and ALT \((P=0.004)\), after adjustment for age, sex, education, lifestyle (smoking status and physical activity) and dietary intake of fruits and vegetables, alcohol, coffee and tea (model III). Daily consumption of 100 mg of chocolate was associated with a reduction of HOMA-IR by 0.16, of serum insulin levels by 0.16 µg/l and of liver enzymes \((\gamma\text{-GT, ALT})\) by >0.10 mg/l. No statistically significant associations of FPG or HbA1c with chocolate consumption were detected, despite the overall negative regression coefficients.

Discussion

To our knowledge, this is the first cross-sectional, population-based study among apparently healthy adults to demonstrate an inverse association between daily chocolate consumption and insulin resistance, serum insulin and liver enzymes, independent of age, sex and socio-economic, lifestyle and dietary factors, including the simultaneous consumption of polyphenol-rich tea and coffee beverages. Daily consumption of 100 mg of chocolate was associated with lower HOMA-IR (by 0.16) and serum insulin (by 0.16 µg/l). Likewise, liver enzyme levels were reduced by about 0.10 mg/l.

Research into the health effects of cocoa has received much attention over the past few years. Several systematic reviews and meta-analyses of existing studies have generally agreed on a potential beneficial association between chocolate consumption and a lower risk for cardiometabolic disorders\(^{(6,30,51)}\).
In ORISCAV-LUX participants, there was no sex-specific difference in chocolate consumption. A higher number of non-consumers were living below the poverty threshold, had lower education levels and were more physically inactive compared with regular chocolate consumers. Chocolate is rich in sugar and fat, contributing to the assumption that frequent consumption may boost obesity. In contrast to traditional beliefs, the present study showed that adiposity measures (BMI, WC), glycaemic parameters (FPG, HbA1c and HOMA-IR) and liver biomarkers (BMI, WC, adiposity measures, HbA1c and HOMA-IR) and insulin sensitivity check index and insulin sensitivity index(35). Our findings are in line with two small-scale interventional trials. The first study demonstrated that chocolate (cocoa powder) may have specific insulinotropic effects, irrespective of the food source or the overall macronutrient composition of the food(34). The second one, a cross-over trial, showed that consumption of flavanols-rich dark chocolate reduced insulin resistance, as measured by three methods: HOMA, quantitative insulin sensitivity check index and insulin sensitivity index(35). Recently, data from a longitudinal study revealed that daily chocolate intake was associated with reduced levels of liver enzymes in HIV–hepatitis C virus co-infected patients(36).

Cocoa and its derivatives contain a specific class of polyphenols named flavanols, which are recognised as having important anti-inflammatory properties, possibly reducing the risk of CHD, cancer and other inflammatory-related diseases(11,37). Cocoa contains more phenolic antioxidants than most foods. Antioxidant effects of cocoa may directly influence insulin resistance and, in turn, reduce diabetes risk(38).

An additional potential mechanism through which cocoa might exert its benefits on insulin sensitivity is dependent, at least in part, on insulin-mediated nitric oxide (NO) release(39). In fact, flavanols may stimulate production of NO from vascular endothelium and mimic metabolic actions of insulin by using signalling pathways partially overlapping with those regulating vasodilator actions of insulin(40). Thus, flavanols and related polyphenolic antioxidants may counteract insulin resistance by increasing NO bioavailability(37,35). The observed association

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Non-consumers</th>
<th>%</th>
<th>Consumers</th>
<th>%</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>210</td>
<td>18.2</td>
<td>943</td>
<td>81.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>103</td>
<td>49.1</td>
<td>476</td>
<td>50.5</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>107</td>
<td>50.9</td>
<td>467</td>
<td>49.5</td>
<td></td>
</tr>
<tr>
<td>Education level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Primary</td>
<td>87</td>
<td>42.03</td>
<td>216</td>
<td>23.15</td>
<td></td>
</tr>
<tr>
<td>Secondary</td>
<td>88</td>
<td>42.5</td>
<td>444</td>
<td>47.6</td>
<td></td>
</tr>
<tr>
<td>Tertiary</td>
<td>32</td>
<td>15.5</td>
<td>273</td>
<td>29.3</td>
<td></td>
</tr>
<tr>
<td>Income</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Below poverty level</td>
<td>53</td>
<td>28.5</td>
<td>158</td>
<td>19.4</td>
<td>0.006</td>
</tr>
<tr>
<td>Current smokers</td>
<td>54</td>
<td>25.7</td>
<td>195</td>
<td>20.7</td>
<td>0.049</td>
</tr>
<tr>
<td>Physical activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactive</td>
<td>45</td>
<td>22.4</td>
<td>142</td>
<td>15.7</td>
<td></td>
</tr>
<tr>
<td>Moderately active</td>
<td>47</td>
<td>23.4</td>
<td>259</td>
<td>28.7</td>
<td></td>
</tr>
<tr>
<td>Active</td>
<td>109</td>
<td>54.2</td>
<td>501</td>
<td>55.5</td>
<td></td>
</tr>
<tr>
<td>Obesity‡</td>
<td>58</td>
<td>27.8</td>
<td>173</td>
<td>18.3</td>
<td>0.002</td>
</tr>
<tr>
<td>Hypertension§</td>
<td>103</td>
<td>49.1</td>
<td>325</td>
<td>34.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes (%)¶</td>
<td>15</td>
<td>7.3</td>
<td>28</td>
<td>3.04</td>
<td>0.0041</td>
</tr>
<tr>
<td>Dyslipidaemia¶</td>
<td>169</td>
<td>82.04</td>
<td>671</td>
<td>72.1</td>
<td>0.23</td>
</tr>
</tbody>
</table>

* Difference in the number of cases is related to missing values for several variables. Physical activity was assessed via scoring criteria of the International Physical Activity Questionnaire.
† P-values for testing the differences among demographic and lifestyle characteristic variables across two groups of chocolate consumption by using j2-test. P > 0.05 considered significant.
‡ Obesity defined as BMI ≥ 30 kg/m2.
§ Hypertension defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or taking antihypertensive medications(27).
¶ Dyslipidaemia was defined as having at least one of the following anomalies: total cholesterol ≥ 190 mg/dl (≥ 4.9 mmol/l)(28).
|| Diabetes defined as taking anti-diabetic medications and/or having fasting plasma glucose ≥ 126 mg/dl (≥ 7 mmol/l)(29) or ≥ 190 mg/dl (≥ 7 mmol/l)(28) or ≥ 150 mg/dl (≥ 7 mmol/l)(28).
|
between increased chocolate consumption and lower levels of ALT, also a marker of inflammation, indirectly confirms previous in vitro results, suggesting that the mechanism through which cocoa may be beneficial to liver cells is more related to its inflammatory effect.

Although our findings and other similar cross-sectional studies have shown an association between daily chocolate consumption and lower BMI, a more recent prospective study, with 3-year follow-up among postmenopausal American women aged 50–79 years, found a direct association between chocolate–candy consumption and weight gain. The divergent findings from these two types of studies could be due to confounding effects of serious chronic diseases. Overweight and obese subjects (presented with higher BMI) may tend to decrease their energy-dense food consumption, owing to awareness of several pathologies (hypertension, lipid disorders, hyperglycaemia or any other reason). This information regarding dieting should help, to some extent, in minimising the potential for reverse causation, and thus avoid a major bias in the observed associations. In our studied sample, chocolate consumption was higher among the younger age group of participants. The relatively healthy profile of chocolate consumers compared with non-consumers may be related to their age, as younger age groups are still healthy and less exposed to age-related pathologies such as diabetes, hypertension and obesity. Adjusting for a wide range of variables including age, sex and socio-economic, lifestyle and dietary factors suggests an independent relationship of these potential confounding factors. These measures may help reduce the potential reverse causality bias.

All glycaemic and hepatic biomarkers of interest were also significantly associated with BMI. After adjusting for BMI in model III, the observed associations were no longer significant (data not shown). In this study, we focused on the examination of the total causal effect. Therefore, it is not only unnecessary but also likely harmful to adjust for a variable (or a proxy of a variable) on a causal path from exposure to disease.
Schisterman et al.\(^{20}\) suggest that one is fairly well protected from analytic pitfalls by avoiding control for factors affected by the exposure.

Metabolic benefits from dark chocolate consumption have been demonstrated with regard to BP as well as total cholesterol and LDL-cholesterol levels in short randomised trials\(^ {17,18}\). In addition, chocolate consumption has been linked to lower cardiovascular and all-cause mortality in prospective observational studies\(^ {15,33}\). The scientific data indicating that cocoa flavonoids may make an important contribution to cardiovascular health continues to grow rapidly. Our findings extend favourable associations of chocolate intake with cardiometabolic factors and insulin sensitivity.

The present study has several important strengths. The data were derived from a recent European nationwide population-based sample. Extensive data on a wide range of potential dietary and lifestyle confounding variables were considered for the multivariable analyses, which have been rarely controlled for in other prospective studies or intervention trials. Furthermore, this is the first study to assess the simultaneous consumption of polyphenol-rich tea and coffee beverages, although residual confounding by additional unknown or unmeasured behavioural or other dietary factors cannot be ruled out.

Multiple components in chocolate, particularly flavonoids, may contribute to the complex interplay between nutrition and health. Cocoa and chocolate contribute to trace-mineral intake, which is necessary for optimum functioning of all biological and vascular systems. In the context of nutrition, this research should be pursued in parallel with further investigation of the potential benefits from chocolate on cognitive and physical health. Our findings add evidence to the growing scientific interest to define nutritional recommendations for dietary polyphenols. Cocoa-based products may offer an extraordinary opportunity to successfully improve compliance to dietary recommendations. Potential applications of this knowledge include recommendations by healthcare professionals to encourage individuals to consume a wide range of phytochemical-rich foods, which can include dark chocolate in moderate amounts\(^ {15,33}\). It is important to differentiate between the natural product cocoa and the processed product chocolate, which refers to the combination of cocoa, sugar and eventually milk and other ingredients into a solid food product\(^ {7}\). Chocolate is an energy-dense food and individuals must keep energy intake and expenditure in mind when including it in their diet, as any excess may cause an increase in weight.

Therefore, physical activity, diet and other lifestyle factors must be carefully balanced to avoid detrimental weight gain over time.

The most predominant limitation of this study was the cross-sectional design. Although the matter of causality cannot be replied, these results may form the basis for generating new hypotheses regarding the relationship between chocolate consumption and insulin resistance and liver enzymes. In addition, despite the intensive efforts to minimise dietary

Table 3. Regression coefficients relating chocolate consumption (100 g/d) to glycaemic and hepatic markers, Observation of Cardiovascular Risk Factors in Luxembourg 2007–2008\(^ {45}\)

(Regression coefficients with their standard errors; \(n \) 1128 subjects)

<table>
<thead>
<tr>
<th>Covariate sets</th>
<th>Daily chocolate consumption (100 g/d)</th>
<th>(b)</th>
<th>se</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FPG (mg/dl)</td>
<td>Model I†</td>
<td>-0.0049</td>
<td>0.0082</td>
<td>0.55</td>
</tr>
<tr>
<td></td>
<td>Model II†</td>
<td>-0.0028</td>
<td>0.0089</td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>Model III§</td>
<td>-0.0027</td>
<td>0.0089</td>
<td>0.76</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>Model I†</td>
<td>-0.002</td>
<td>0.0041</td>
<td>0.62</td>
</tr>
<tr>
<td></td>
<td>Model II†</td>
<td>-0.0062</td>
<td>0.0045</td>
<td>0.17</td>
</tr>
<tr>
<td></td>
<td>Model III§</td>
<td>-0.0062</td>
<td>0.0045</td>
<td>0.17</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>Model I†</td>
<td>-0.1718</td>
<td>0.0523</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>Model II†</td>
<td>-0.1688</td>
<td>0.0572</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td>Model III§</td>
<td>-0.1644</td>
<td>0.0573</td>
<td>0.004</td>
</tr>
<tr>
<td>Insulin (µg/l)</td>
<td>Model I†</td>
<td>-0.1633</td>
<td>0.0488</td>
<td>0.0008</td>
</tr>
<tr>
<td></td>
<td>Model II†</td>
<td>-0.1602</td>
<td>0.0533</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td>Model III§</td>
<td>-0.157</td>
<td>0.0533</td>
<td>0.003</td>
</tr>
<tr>
<td>(\gamma)-GT (mg/l)</td>
<td>Model I†</td>
<td>-0.1163</td>
<td>0.043</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>Model II†</td>
<td>-0.1198</td>
<td>0.0461</td>
<td>0.009</td>
</tr>
<tr>
<td>AST (mg/l)</td>
<td>Model I†</td>
<td>-0.1199</td>
<td>0.0459</td>
<td>0.009</td>
</tr>
<tr>
<td></td>
<td>Model II†</td>
<td>-0.0264</td>
<td>0.0212</td>
<td>0.21</td>
</tr>
<tr>
<td></td>
<td>Model III§</td>
<td>-0.0394</td>
<td>0.0229</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td>Model III§</td>
<td>-0.0399</td>
<td>0.0228</td>
<td>0.08</td>
</tr>
<tr>
<td>ALT (mg/l)</td>
<td>Model I†</td>
<td>-0.0666</td>
<td>0.0319</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td>Model II†</td>
<td>-0.0972</td>
<td>0.0343</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td>Model III§</td>
<td>-0.0983</td>
<td>0.0341</td>
<td>0.004</td>
</tr>
</tbody>
</table>

FPG, fasting plasma glucose; HbA1c, glycated Hb; HOMA-IR, homoeostasis model assessment of insulin resistance; \(\gamma\)-GT, \(\gamma\)-glutamyl-transpeptidase; AST, aspartate transaminase; ALT, alanine transaminase.

* Subjects taking anti-diabetic medications \((n = 25)\) were excluded from glycaemic biomarker models (FPG, HbA1c, HOMA-IR and insulin).
† Model II: adjusted for age, sex, education.
‡ Model III: adjusted for covariates in model II + coffee and tea consumption.
reporting inaccuracies through staff training and extensive control procedures.\(^3\)\(^9\) Self-reported data may be subject to misclassification and recall errors. Different chocolate products yield different amounts of fat, sugar and energy content. Unfortunately, no data were available about the types of chocolate consumed or the amount of flavonols present in finished food products. Likewise, we do not have information about the consumption of cocoa beverages such as milkshakes, hot cocoa, etc., which may confound some drawbacks to our findings.

In conclusion, this study presents some novel findings, supporting a potential beneficial effect of daily chocolate consumption on insulin sensitivity and hepatic biomarkers. Taking the cross-sectional study design into account, further observational prospective research and well-designed randomised-controlled studies are needed to confirm this relationship and to comprehend the role and mechanisms that different types of chocolate may play in insulin resistance and cardiometabolic disorders.

Acknowledgements
The authors are grateful to Stephen Senn for his valuable comments on the statistical analyses and revision of the manuscript. A. A. is supported by a grant from the Fond National de Recherche for the DIQUA-LUX project (5870404), Luxembourg (Assessment of Diet Quality of the General Population in Luxembourg and its Association with Cardiometabolic Risk). G. E. C. is supported by a Sidney Sax Research Fellowship (National Health and Medical Research Council, Australia; grant no. APP1054567). The funding sources had no involvement in the study design or in the collection, analysis and interpretation of data.

A. A. was involved in the conception and design of the ORISCAV-LUX study, coordinated the field data collection, conceived the present research, performed the statistical analyses and drafted the manuscript. N. S. contributed to the statistical analyses and data interpretation. G. E. C., M. F. E. and S. S. contributed to the critical revisions of the intellectual content of the manuscript. All the authors approved the final version of the manuscript.

There are no conflicts of interest to declare.

References
2. Steinberger J & Daniels SR, American Heart Association Atherosclerosis Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young). et al. (2003) Obesity, insulin resistance, diabetes, and cardiometabolic risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107, 1448–1453.